Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Amount Of Epithelioid Differentiation Is a Predictor Of Survival In Malignant Pleural Mesothelioma.

W. Vigneswaran, Diana Y. Kircheva, V. Ananthanarayanan, S. Watson, Qudsia Arif, A. D. Celauro, H. Kindler, A. Husain
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Macroscopic complete surgical resection with adjuvant chemotherapy can provide a survival advantage in patients with malignant pleural mesothelioma (MPM). Patients with nonepithelioid histology are largely excluded from such radical operations even though they might benefit. The degree of epithelioid differentiation varies in biphasic histology. We report the outcomes of pleurectomy and decortication and the effect of epithelioid differentiation on overall survival of patients with MPM. METHODS This report is based on the outcomes of 144 patients who underwent pleurectomy and decortication at a single institution between 2008 and 2015. The variables assessed were age, gender, histology, and pathologic T and N stage. No patients with pure sarcomatoid histology were included. Two independent pathologists estimated the percentage of epithelioid histology. A Cox regression model was used to identify significant predictors of survival. The Kaplan-Meier method was used to summarize overall and subgroup survival. RESULTS Included were 116 men and 28 women with a median age of 69 years (range, 43 to 88 years). The 2-year survival from pleurectomy and decortication was 20%. Median survival overall was 13.34 months and was 20.1 months for the 100% epithelioid subgroup (n = 77), 11.8 months for the 51% to 99% epithelioid subgroup (n = 39), and 6.62 months for the less than 50% epithelioid subgroup (n = 28). The amount of epithelioid differentiation was a significant predictor of survival (p < 0.001). Differences in survival based on the T, but N stage, were not statistically significant. CONCLUSIONS The percentage of epithelioid differentiation is an independent predictor of survival in MPM and should be taken into careful consideration when recommending surgical treatment for patients with biphasic MPM.
This paper references
10.5858/arpa.2010-0604-RA
Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.
P. Betta (2012)
10.1097/JTO.0b013e3182208e3f
Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma: A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group
D. Rice (2011)
10.1097/JTO.0000000000000181
Supplementary Prognostic Variables for Pleural Mesothelioma
H. Pass (2014)
10.1016/0007-0971(83)90068-2
Malignant mesothelioma 1982: review of 4710 published cases.
G. Hillerdal (1983)
10.3978/j.issn.2225-319X.2012.11.10
Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database.
V. Rusch (2012)
10.1016/j.ejcts.2009.08.027
Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma.
Alexandra Schramm (2010)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1016/j.athoracsur.2012.05.102
Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma.
N. Mollberg (2012)
10.1097/00000441-200501000-00007
Malignant pleural mesothelioma.
R. Hughes (2005)
10.1097/PAT.0b013e32834642da
Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma
S. Kao (2011)
10.1016/j.ejcts.2010.12.024
Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
D. Sugarbaker (2011)
10.1016/j.jtcvs.2014.03.011
Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality.
B. Burt (2014)
10.1016/J.HUMPATH.2005.01.019
D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma.
N. Ordóñez (2005)
Tumors and pseudotumors of the serous membranes
W. Mccaughey (1985)
10.1097/JTO.0000000000000663
Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.
W. Travis (2015)
WHO classification of tumours of the lung, pleura, thymus and heart
W. Travis (2015)
10.1037/0033-2909.86.2.420
Intraclass correlations: uses in assessing rater reliability.
P. Shrout (1979)
10.1016/J.HUMPATH.2006.11.008
Recommendations for the reporting of pleural mesothelioma.
K. Butnor (2007)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1007/BF02306613
Surgically debulked malignant pleural mesothelioma: Results and prognostic factors
H. Pass (2006)
10.1016/j.athoracsur.2009.01.026
Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma.
T. Yan (2009)



This paper is referenced by
10.21037/TLCR.2020.03.38
Clinical significance of histologic subtyping of malignant pleural mesothelioma.
L. Brčić (2020)
10.21037/shc.2018.03.15
Should the surgical decision be influenced by the diagnostic biopsy in mesothelioma
J. Anderson (2018)
10.1016/j.athoracsur.2018.09.019
Differential Survival Characteristics of Sarcomatoid Subtype in Biphasic Pleural Mesothelioma.
L. Harling (2019)
10.1055/s-0039-1693406
Malignant Mesothelioma: Has Anything Changed?
Roger Y Kim (2019)
10.1016/j.thorsurg.2020.08.005
The Molecular Basis of Malignant Pleural Mesothelioma.
Benjamin Wadowski (2020)
10.1093/ejcts/ezy258
ERS/EACTS statement on the management of malignant pleural effusions
A. Bibby (2019)
10.1038/s41379-019-0320-y
Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas
S. Dacic (2019)
10.1097/MCP.0000000000000389
Surgery as part of radical treatment for malignant pleural mesothelioma
D. Waller (2017)
10.21037/TLCR-19-620
Update on the pathologic diagnosis of malignant mesothelioma.
J. Schulte (2020)
10.1007/s00268-017-4264-4
Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma
W. Vigneswaran (2017)
10.1016/j.intimp.2020.106481
Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis.
F. Zhang (2020)
10.1016/j.humpath.2018.07.003
IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.
S. Hui (2018)
10.1016/j.jtho.2019.08.2506
EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach.
A. Nicholson (2019)
10.1016/j.jtocrr.2020.100093
Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms
P. Szlosarek (2020)
10.1016/j.jtcvs.2019.08.027
Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
F. Lococo (2019)
10.1016/j.jtho.2019.06.020
Pathologic considerations and standardization in mesothelioma clinical trials.
M. Tsao (2019)
10.1007/978-3-030-16884-1_7
Pathological Diagnosis of Mesothelioma
G. Fontanini (2019)
10.3389/fgene.2020.00899
Identification of a Five-Gene Signature for Predicting Survival in Malignant Pleural Mesothelioma Patients
Yiyang Bai (2020)
10.1183/13993003.00349-2018
ERS/EACTS statement on the management of malignant pleural effusions
A. Bibby (2018)
10.21037/jtd.2017.10.125
The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review.
G. Alí (2018)
10.1155/2017/2782590
Life Expectancy in Pleural and Peritoneal Mesothelioma
R. Shavelle (2017)
10.3892/ol.2020.11505
Survivin expression as an independent predictor of overall survival in malignant peritoneal mesothelioma
Guo-zun Zhang (2020)
Semantic Scholar Logo Some data provided by SemanticScholar